Pfizer’s Zavicefta, sole CRE antibiotic in KOR, gets reimb
By Son, Hyung-Min | translator Kim, Jung-Ju
24.02.21 14:16:54
가나다라
0
Pfizer held a press conference to commemorate the reimbursement coverage of Zavicefta in Korea
Zavicefta showed non-inferiority compared to existing antibiotics, including carbapenem and meropenem
CRE patients are steadily increasing, with 30,000 patients reported in 2022. “It is necessary to manage patients with antibiotic resistance”
▲From the left, Professor Lee Dong-gun, Professor Yoon Young-kyung, and Pfizer Korea Medical Lead Choi Heeyeon.
A new antibiotic has been added to the insurance reimbursement listing a year after Zerbaxa. Zavicefta, developed by Pfizer, is the only antibiotic that can be used to treat carbapenem-resistant Enterobacteriaceae (CRE). Experts have stressed the use of this drug only when necessary because there is a growing number of patients with antibiotic resistance.
Pfizer Korea hosted a press conference at JW Marriot Seoul on the 21st to commemorate the reimbursement coverage of the new antibiotic drug, Zavicefta. Zavicefta is a combination of ‘ceftazidime,’ a third-generation cephalosporins-class antibiotic, and ‘avibactam,’ used to maintain microbial clearance.
Zavicefta is the only
Son, Hyung-Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)